C

CG Oncology
D

CGON

43.290
USD
-1.13
(-2.54%)
مغلق
حجم التداول
41,387
الربح لكل سهم
-2
العائد الربحي
-
P/E
-24
حجم السوق
3,300,757,781
المقالات

العنوان: CG Oncology

القطاع: Healthcare
الصناعة: Biotechnology
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.